Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
DMAC Stock Forecast 2026-2027
$8.60
Current Price
$447.87M
Market Cap
Buy 5
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to DMAC Price Targets
+190.7%
To High Target of $25.00
+51.2%
To Median Target of $13.00
+27.9%
To Low Target of $11.00
DMAC Price Momentum
+3.0%
1 Week Change
-0.8%
1 Month Change
+59.9%
1 Year Change
+8.0%
Year-to-Date Change
-17.5%
From 52W High of $10.42
+169.6%
From 52W Low of $3.19
📊 TOP ANALYST CALLS
Did DMAC Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if DiaMedica is one of their latest high-conviction picks.
Latest DMAC Stock Price Targets & Analyst Predictions
Based on our analysis of 8 Wall Street analysts, DMAC has a bullish consensus with a median price target of $13.00 (ranging from $11.00 to $25.00). The overall analyst rating is Strong Buy (10.0/10). Currently trading at $8.60, the median forecast implies a 51.2% upside. This outlook is supported by 5 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Josh Schimmer at Cantor Fitzgerald, projecting a 190.7% upside. Conversely, the most conservative target is provided by Chase Knickerbocker at Craig-Hallum, suggesting a 27.9% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
DMAC Analyst Ratings
5
Buy
0
Hold
0
Sell
DMAC Price Target Range
Low
$11.00
Average
$13.00
High
$25.00
Current: $8.60
Latest DMAC Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for DMAC.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Nov 14, 2025 | Cantor Fitzgerald | Josh Schimmer | Overweight | Initiates | $25.00 |
| Aug 15, 2025 | HC Wainwright & Co. | Matthew Caufield | Buy | Reiterates | $12.00 |
| Jul 18, 2025 | Craig-Hallum | Chase Knickerbocker | Buy | Maintains | $11.00 |
| Jul 18, 2025 | Lake Street | Thomas Flaten | Buy | Maintains | $14.00 |
| Jul 18, 2025 | HC Wainwright & Co. | Matthew Caufield | Buy | Maintains | $12.00 |
| May 29, 2025 | HC Wainwright & Co. | Matthew Caufield | Buy | Reiterates | $10.00 |
| Mar 19, 2025 | HC Wainwright & Co. | Matthew Caufield | Buy | Maintains | $10.00 |
| Nov 15, 2024 | HC Wainwright & Co. | Matthew Caufield | Buy | Reiterates | $7.00 |
| Oct 10, 2024 | HC Wainwright & Co. | Matthew Caufield | Buy | Reiterates | $7.00 |
| Oct 7, 2024 | HC Wainwright & Co. | Matthew Caufield | Buy | Initiates | $7.00 |
| Aug 16, 2024 | Oppenheimer | Francois Brisebois | Outperform | Reiterates | $6.00 |
| Apr 24, 2024 | Craig-Hallum | Alexander Nowak | Buy | Assumes | $8.00 |
| Mar 21, 2024 | Craig-Hallum | Alexander Nowak | Buy | Maintains | $8.00 |
| Mar 21, 2024 | Oppenheimer | Francois Brisebois | Outperform | Reiterates | $6.00 |
| Jun 22, 2023 | Oppenheimer | Francois Brisebois | Outperform | Upgrade | $7.00 |
| Jul 7, 2022 | Craig-Hallum | Alexander Nowak | Buy | Maintains | $12.00 |
| Jul 7, 2022 | Lake Street | Thomas Flaten | Buy | Maintains | $8.00 |
| Jul 7, 2022 | Oppenheimer | Francois Brisebois | Perform | Downgrade | $N/A |
| Jun 30, 2021 | Roth Capital | Elemer Piros | Buy | Maintains | $32.00 |
| Apr 9, 2021 | Oppenheimer | Outperform | Initiates | $N/A |
DiaMedica Therapeutics Inc. (DMAC) Competitors
The following stocks are similar to DiaMedica based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
DMAC
DiaMedica
mkt cap
424.95M
DiaMedica Therapeutics Inc. (DMAC) Financial Data
DiaMedica Therapeutics Inc. has a market capitalization of $447.87M with a P/E ratio of -14.3x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -64.1%.
Valuation Metrics
Market Cap
$447.87M
Enterprise Value
$368.86M
P/E Ratio
-14.3x
PEG Ratio
-1.1x
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+12.3%
Current Ratio
10.7x
Debt/Equity
0.5x
ROE
-64.1%
ROA
-38.3%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
DiaMedica Therapeutics Inc. (DMAC) Business Model
About DiaMedica Therapeutics Inc.
What They Do
Develops therapies for neurological and kidney disorders.
Business Model
DiaMedica Therapeutics Inc. operates as a clinical-stage biopharmaceutical company, focusing on the research and development of innovative therapies. The company primarily generates revenue through the development and eventual commercialization of its investigational drugs, targeting unmet medical needs in neurological disorders and chronic kidney diseases.
Additional Information
The company's lead product candidate addresses acute ischemic stroke and chronic kidney disease, indicating a strong market potential. As a public entity, DiaMedica is positioned within the biotechnology sector, contributing to significant advancements in medical research and disease management.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
27
CEO
Mr. Dietrich John Pauls MBA
Country
United States
IPO Year
2018
Website
www.diamedica.comDiaMedica Therapeutics Inc. (DMAC) Latest News & Analysis
Latest News
DiaMedica Therapeutics Provides DM199 Preeclampsia Program Update Following Pre-IND Meeting with FDA
28 days ago
Quick Summary
DiaMedica Therapeutics Inc. completed a pre-IND meeting with the FDA regarding DM199 for preeclampsia, with the FDA requesting one additional non-clinical study before proceeding.
Why It Matters
Completion of the FDA pre-IND meeting signals progress for DiaMedica's drug DM199, potentially enhancing its market prospects and impacting stock value positively.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
DiaMedica Therapeutics Inc. (DMAC) will hold its Q3 2025 earnings call on November 13, 2025, at 8:00 AM EST, featuring key company executives and analysts from various research divisions.
Why It Matters
The earnings call provides insights into DiaMedica's financial performance and strategic direction, influencing investor sentiment and stock valuation.
Source: Seeking Alpha
Market Sentiment:
Neutral
DiaMedica Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Highlights
2 months ago
Quick Summary
DiaMedica Therapeutics Inc. (Nasdaq: DMAC) reported Q3 financial results and will hold a conference call on November 13, 2025, to discuss business updates.
Why It Matters
DiaMedica's focus on treatments for serious conditions could drive future growth. Financial results and an upcoming call may indicate performance and strategic direction, impacting stock valuation.
Source: Business Wire
Market Sentiment:
Neutral
DiaMedica Therapeutics to Participate in the Jefferies Global Healthcare Conference in London
2 months ago
Quick Summary
DiaMedica Therapeutics Inc. (Nasdaq: DMAC) will have CEO Rick Pauls at the Jefferies Global Healthcare Conference in London from Nov 17-20, 2025, for a presentation and investor meetings.
Why It Matters
Rick Pauls' participation in the Jefferies Global Healthcare Conference could enhance DiaMedica's visibility, attract investor interest, and potentially impact stock performance.
Source: Business Wire
Market Sentiment:
Neutral
DiaMedica Therapeutics to Report Third Quarter 2025 Financial Results and Provide a Business Update November 13, 2025
2 months ago
Quick Summary
DiaMedica Therapeutics Inc. (Nasdaq: DMAC) will release Q3 2025 financial results on November 12, 2025, after market close, and host a conference call on November 13 at 8 AM ET.
Why It Matters
The announcement of DiaMedica's Q3 2025 financial results and conference call could influence investor sentiment, as it will provide insights into the company's performance and future prospects.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
DiaMedica Therapeutics Inc. granted stock options for 490,000 shares to five new non-executive employees, effective September 18, 2025.
Why It Matters
The grant of stock options to new employees may signal confidence in DiaMedica's future growth, potentially enhancing employee motivation and aligning their interests with shareholders.
Source: Business Wire
Market Sentiment:
Neutral
Frequently Asked Questions About DMAC Stock
What is DiaMedica Therapeutics Inc.'s (DMAC) stock forecast for 2026?
Based on our analysis of 8 Wall Street analysts, DiaMedica Therapeutics Inc. (DMAC) has a median price target of $13.00. The highest price target is $25.00 and the lowest is $11.00.
Is DMAC stock a good investment in 2026?
According to current analyst ratings, DMAC has 5 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $8.60. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for DMAC stock?
Wall Street analysts predict DMAC stock could reach $13.00 in the next 12 months. This represents a 51.2% increase from the current price of $8.60. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is DiaMedica Therapeutics Inc.'s business model?
DiaMedica Therapeutics Inc. operates as a clinical-stage biopharmaceutical company, focusing on the research and development of innovative therapies. The company primarily generates revenue through the development and eventual commercialization of its investigational drugs, targeting unmet medical needs in neurological disorders and chronic kidney diseases.
What is the highest forecasted price for DMAC DiaMedica Therapeutics Inc.?
The highest price target for DMAC is $25.00 from Josh Schimmer at Cantor Fitzgerald, which represents a 190.7% increase from the current price of $8.60.
What is the lowest forecasted price for DMAC DiaMedica Therapeutics Inc.?
The lowest price target for DMAC is $11.00 from Chase Knickerbocker at Craig-Hallum, which represents a 27.9% increase from the current price of $8.60.
What is the overall DMAC consensus from analysts for DiaMedica Therapeutics Inc.?
The overall analyst consensus for DMAC is bullish. Out of 8 Wall Street analysts, 5 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $13.00.
How accurate are DMAC stock price projections?
Stock price projections, including those for DiaMedica Therapeutics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: January 15, 2026 8:54 AM UTC